DOCSLIB.ORG

List of "Designated Substances" in Japan (As of August 25, 2021)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of List of "Designated Substances" in Japan (as of October 8, 2021) Drug category, "Designated Substances (*)" was newly established in 2007 to control new psychoactive substances (NPS). Their manufacture, import, sale, display, possession, use etc. are generally prohibited except for scietific purposes. A total 2392 substances including 2 plants (Salvia Divinorum and Mitragina Speciosa (Kratom)) are currently controlled as "Designated Substances". (Substances basis 299, Generic scheduling 2098) 69 substances, such as JWH-018, mephedrone, MDPV etc. have been already reclassified to be "Narcotics". (*)They are controlled by "The Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices". No. Name Other Name Chemical Structure Date of Enforcement 1 Isobutyl nitrite April 1, 2007 ONO 2 Isopropyl nitrite April 1, 2007 ONO 3 Isopentyl nitrite Isoamyl nitrite April 1, 2007 ONO 4 tert-Butyl nitrite April 1, 2007 ONO ONO 5 Cyclohexyl nitrite April 1, 2007 6 Butyl nitrite April 1, 2007 ONO N O 4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9- 7 ALD-52 N February 28, 2020 hexahydroindolo[4,3-fg]quinoline-9-carboxamide N O O O 8 4-Acetoxy-N -isopropyl-N- metyltryptamine 4-AcO-MIPT N April 4, 2015 N H O O 9 4-Acetoxy-N -ethyl-N -methyltryptamine 4-AcO-MET N August 8, 2015 N H O O 10 4-Acetoxy-N ,N -diallyltryptamine 4-AcO-DALT N August 8, 2015 N H O O 11 4-Acetoxy-N ,N -diisopropyltryptamine 4-AcO-DIPT N April 1, 2007 N H O O 12 4-Acetoxy-N,N -diethyltryptamine 4-AcO-DET N August 8, 2015 N H O O 13 4-Acetoxy-N,N -dimethyltryptamine 4-AcO-DMT N August 8, 2015 N H O N H N N -(1-Adamantyl)-1-(5-chloropentyl)-1H -indazole-3- APINACA N -(5- N 14 April 18, 2016 carboxamide chloropentyl) analog Cl 1 No. Name Other Name Chemical Structure Date of Enforcement N -(1-Adamantyl)-1-[(tetrahydro-2H -pyran-4-yl)methyl]-1H - Adamantyl-THPINACA 15 March 6, 2017 indazole-3-carboxamide ATHPINACA O Adamantyl-THPINACA 2- N N -(2-Adamantyl)-1-[(tetrahydro-2H -pyran-4-yl)methyl]-1H - adamantyl isomer H N 16 indazole-3-carboxamide ATHPINACA 2-adamantyl N March 6, 2017 isomer O O N H N -(1-Adamantyl)-1-(4-fluorobenzyl)-1H -indazole-3- N 17 carboxamide FUB-APINACA N January 5, 2015 F O N H APICA N-(5-fluoropentyl) N -(1-Adamantyl)-1-(5-fluoropentyl)-1H -indole-3- N 18 derivative May 30, 2013 carboxamide STS-135 F O N H N APINACA N 19 N -(1-Adamantyl)-1-pentyl-1H -indazole-3-carboxamide July 1, 2012 AKB48 O O N 20 1-Adamantyl 1-pentyl-1H -indazole-3-carboxylate ACBL(N)-018 N December 29, 2017 O N 21 1-Adamantyl(1-pentyl-1H -indol-3-yl)methanone AB-001 May 30, 2013 O N H APICA N 22 N -(1-Adamantyl)-1-pentyl-1H -indole-3-carboxamide July 1, 2012 2NE1 O 1-Adamantyl{1-[(1-methylpiperidin-2-yl)methyl]-1H -indol-3- 23 AM1248 N May 30, 2013 yl｝methanone N O H2N N -(1-Amino-1-oxo-3-phenylpropan-2-yl)-1- APP-CHMINACA N 24 H September 3, 2016 (cyclohexylmethyl)-1H -indazole-3-carboxamide PX-3 O N N 2 No. Name Other Name Chemical Structure Date of Enforcement O H2N N N -(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4-fluorobenzyl)- H 25 FU-PX-2 August 29, 2015 1H -indazole-3-carboxamide O N N F O H2N N H N -(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)- O N 26 PX-2 November 28, 2014 1H -indazole-3-carboxamide N F O H2N N N -(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)- H O 27 1H -indole-3-carboxamide PX-1 N November 28, 2014 F O H2N N N -(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1- ADB-CHMICA、 H 28 O February 19, 2019 (cyclohexylmethyl)-1H -indole-3-carboxamide MAB-CHMICA N N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H- 29 ADB-BUTINACA March 15,2021 indazole-3-carboxamide O H2N N H N -(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5- O N 30 fluoropentyl)-1H -indazole-3-carboxamide 5F-ADB-PINACA N November 28, 2014 F O H2N N H N -(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5- O 31 fluoropentyl)-1H -indole-3-carboxamide 5-fluoro-ADBICA N February 9, 2015 F O H2N N N -(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H - H O N 32 indazole-3-carboxamide ADB-PINACA N July 11, 2014 O H2N N H O N N -(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H - N 33 ADBICA May 30, 2013 indole-3-carboxamide 3 No. Name Other Name Chemical Structure Date of Enforcement O O NH 2 34 2-Amino-1-(4-bromo-2,5-dimethoxyphenyl)ethanone bk-2C-B April 4, 2015 Br O O H2N N H O N N -(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-chloropentyl)- N 35 5Cl-AB-PINACA November 8, 2014 1H -indazole-3-carboxamide Cl O H2N N N -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(2-fluorobenzyl)- H AB-FUBINACA 2- O N 36 1H -indazole-3-carboxamide N December 5, 2015 fluorobenzyl isomer F O H2N N H N -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)- O N N 37 1H -indazole-3-carboxamide 5‐Fluoro‐AB‐PINACA July 11, 2014 F O H2N N H O N -(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)- N 38 5-Fluoro-ABICA August 25, 2014 1H -indole-3-carboxamide F O NH 2 39 2-(4-Allyloxy-3,5-dimethoxyphenyl)ethanamine Allylescaline April 4, 2015 O O N O 7-Allyl-N,N-diethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg] 40 quinoline-9-carboxamide AL-LAD February 28, 2020 N HN O NH2 41 1-(4-Isopropylsulfanyl- 2,5-dimethoxyphenyl)propan-2-amine ALEPH-4 May 14, 2011 S O N 42 N -Isopropyl-N -methyltryptamine MIPT April 1, 2007 N H O N 43 N -Isopropyl-5-methoxy-N -methyltryptamine 5-MeO-MIPT April 1, 2007 N H 44 Nitrous oxide SIVAGUS N2O February 28, 2016 45 Indan-2-amine 2-AI January 11, 2008 NH2 O α-PBP indane analog N 46 1-(Indan-5-yl)-2-(pyrrolidin-1-yl)butan-1-one February 9, 2015 5-PPDI 4 No. Name Other Name Chemical Structure Date of Enforcement O N α-PHP indane analog 47 1-(Indan-5-yl)-2-(pyrrolidin-1-yl)hexan-1-one February 27, 2015 5-BPDI (1H -Indol-3-yl)(2,2,3,3-tetramethylcycropropan-1- 48 DP-UR-144 September 29, 2014 yl)methanone NH2 5-API 49 1-(1H -Indol-5-yl)propan-2-amine January 16, 2013 5-IT N H O H N 50 2-(Ethylamino)-1-(indan-5-yl)butan-1-one bk-IBP February 9, 2015 O H N 51 2-(Ethylamino)-1-(indan-5-yl)pentan-1-one bk-IVP February 9, 2015 52 3-[1-(Ethylamino)cyclohexyl]phenol 3-HO-PCE HO December 17, 2019 HN 53 2-(Ethylamino)-2-(thiophen-2-yl)cyclohexanone Tiletamine March 6, 2017 Deschloro-N-ethyl- ketamine 54 2-(Ethylamino)-2-phenylcyclohexanone Eticyclidone September 1, 2018 O-PCE 2-Oxo-PCE O N 55 N -Ethyl-N -isopropyl-5-methoxytryptamine 5-MeO-EIPT January 16, 2009 N H H N Ephenidine 56 N -Ethyl-1,2-diphenylethylamine EPE November 11, 2016 NEDPA O NH2 57 2-(4-Ethyl-2,5-dimethoxyphenyl)ethanamine 2C-E April 1, 2007 O O H 2-(4-Ethyl-2,5-dimethoxyphenyl)-N -(2-methoxybenzyl) N 58 ethanamine 25E-NBOMe June 1, 2015 O O 59 ２－［（４－Ethyl－２，５－dimethoxyphenethylamino）methyl］phenol 25E-NBOH December 19, 2018 O NH2 60 1-(4-Ethylsulfanyl-2,5-dimethoxyphenyl)propan-2-amine ALEPH-2 January 16, 2009 S O 5 No. Name Other Name Chemical Structure Date of Enforcement HO N 61 N -Ethyl-4-hydroxy-N -methyltryptamine 4-OH-MET April 4, 2015 N H H 62 1-（4-Ethylphenyl）-N -(2-methoxybenzyl)propan-2-amine 4-EA-NBOMe N December 29, 2017 O 63 Ethyl 2-(4-fluorophenyl)-2-(piperidin-2-yl)acetate 4-Fluoroethylphenidate March 15,2021 H N 2-FEA 64 N -Ethyl-1-（2-fluorophenyl）propan-2-amine February 19, 2019 2-fluoroethamphetamine F 3-FEA 65 N- Ethyl-1-（3-fluorophenyl）propan-2-amine November 24, 2018 3-fluoroethamphetamine 4-FEA 66 N -Ethyl-1-（4-fluorophenyl）propan-2-amine November 24, 2018 4-fluoroethamphetamine 3F-Phenetrazine 67 3-Ethyl-2-(3-fluorophenyl)morpholine September 8, 2017 3-FPE O O N H Ethyl 2-[1-(4-fluorobenzyl)-1H -indazole-3-carboxamido]-3- EMB-FUBINACA O N 68 September 3, 2016 methylbutanoate FUB-AEB N F O O N H O N Ethyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3- N 69 5F-EDMB-PINACA January 22, 2021 dimethylbutanoate F O O N H Ethyl 2-[1-(5-fluoropentyl)-1H -indazole-3-carboxamido]- O N 70 3-methylbutanoate 5F-AEB N July 2, 2016 F O O N H O Ethyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3- N 71 5F-EMB-PICA, EMB-2201 August 25, 2021 methylbutanoate F 6 No.
Load more

Recommended publications
  • Peakal: Protons I Have Known and Loved — Fifty Shades of Grey-Market Spectra
    PeakAL: Protons I Have Known and Loved — Fifty shades of grey-market spectra Stephen J. Chapman* and Arabo A. Avanes * Correspondence to: Isomer Design, 4103-210 Victoria St, Toronto, ON, M5B 2R3, Canada. E-mail: [email protected] 1H NMR spectra of 28 alleged psychedelic phenylethanamines from 15 grey-market internet vendors across North America and Europe were acquired and compared. Members from each of the principal phenylethanamine families were analyzed: eleven para- substituted 2,5-dimethoxyphenylethanamines (the 2C and 2C-T series); four para-substituted 3,5-dimethoxyphenylethanamines (mescaline analogues); two β-substituted phenylethanamines; and ten N-substituted phenylethanamines with a 2-methoxybenzyl (NBOMe), 2-hydroxybenzyl (NBOH), or 2,3-methylenedioxybenzyl (NBMD) amine moiety. 1H NMR spectra for some of these compounds have not been previously reported to our knowledge. Others have reported on the composition of “mystery pills,” single-dose formulations obtained from retail shops and websites. We believe this is the first published survey of bulk “research chemicals” marketed and sold as such. Only one analyte was unequivocally misrepresented. This collection of experimentally uniform spectra may help forensic and harm-reduction organizations identify these compounds, some of which appear only sporadically. The complete spectra are provided as supplementary data.[1] Keywords: 1H NMR, drug checking, grey markets, research chemicals, phenylethanamines, N-benzyl phenylethanamines, PiHKAL DOI: http://dx.doi.org/10.16889/isomerdesign-1 Published: 1 August 2015 Version: 1.03 “Once you get a serious spectrum collection, Nevertheless, an inherent weakness of grey markets is the the tendency is to push it as far as you can.”1 absence of regulatory oversight.
    [Show full text]
  • Synthetic Cannabinoids-1) IMMUNALYSIS DIRECT ELISA Kit for Forensic Matrices
    K2 (Synthetic IMMUNALYSIS Cannabinoids-1) DIRECT ELISA Kit for forensic matrices JWH-018 Demonstrates significant cross reactivity with the major metabolites of JWH-018, JWH-073, Schedule I Controlled Substances: JWH-018, JWH-073, JWH-200, JWH-019, JWH-200 and AM-2201. JWH-122, JWH-398, JWH-081, JWH-250, JWH-203 CP-47,497, CP-47,497 C8, HU-210, HU-211, AM-2201, AM-694, RCS-4 (SR-19), RCS-8 (SR-18) Street Names: Spice, K2, Genie, Yucatan Fire, Skunk, Sence, Smoke, ChillX, Highdi’s Almdröhner, Earth Impact, Gorillaz, Galaxy Gold, Space Truckin, Solar Flare, Moon Rocks, Blue Lotus, Aroma, Scope, Sky, OG Potpourri, Bliss, Black Momba, Bombay Blue, Fake Weed, and Zohai. Urine About Synthetic Cannabinoids: Spice or K2 is a mixture of herbs and spices treated with synthetic compounds similar to THC that is typically sold in head shops, tobacco shops or over the internet. Though not structurally related, K2 mimics the psychoactive stimulant properties of THC but can be 100 to 800 times more potent than THC.1 Administration: Synthetic Cannabinoid products are usually smoked in joints or pipes, and sometimes made into tea.2 Effects: Psychological effects are similar to those of marijuana and include paranoia, panic attacks and giddiness. Physiological effects include increased heart rate and high blood pressure. Long-term effects are not known.2 1. Devane, W. A. et al. A novel probe for the cannabi- noid receptor. Journal of Medical Chemistry 35 (11): 2065–2069 (1992). 2. Drug Enforcement Administration; www.dea.gov. Tel 909.482.0840 | Toll Free
    [Show full text]
  • Swedish Code of Statutes
    1. ------IND- 2018 0506 S-- EN- ------ 20190508 --- --- FINAL Swedish Code of Statutes Ordinance amending the Ordinance (1999:58) banning certain products SFS 2018:1587 that are harmful to health Published Issued on 4 October 2018 on 9 October 2018 The Government hereby lays down1 that the annex to the Ordinance (1999:58) prohibiting certain products that are harmful to health shall read as set out below. ___________ This ordinance shall enter into force on 12 November 2018. On behalf of the government ANNIKA STRANDHÄLL Kjell Rempler (Ministry of Health and Social Affairs) 1 See Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services. 2 Annex SFS 2018:1587 List of products to be regarded as products that are harmful to health in accordance with the Ordinance prohibiting certain products that are harmful to health N-methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine (MBDB) 1-(3,4-methylenedioxyphenyl)-2-butylamine (BDB) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT) 5-methoxy-alphamethyltryptamine (5-MeO-AMT) 2,5-dimethoxy-4-ethylphenethylamine (2C-E) alpha-methyltryptamine (AMT) 2,5-dimethoxy-4-chlorophenethylamine (2C-C) 2,5-dimethoxy-4-methylphenethylamine (2C-D) 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT) gamma-butyrolactone (GBL) 1,4-butanediol (1,4-BD) 4-acetoxy-N,N-methylisopropyltryptamine
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Aldrich Raman
    Aldrich Raman Library Listing – 14,033 spectra This library represents the most comprehensive collection of FT-Raman spectral references available. It contains many common chemicals found in the Aldrich Handbook of Fine Chemicals. To create the Aldrich Raman Condensed Phase Library, 14,033 compounds found in the Aldrich Collection of FT-IR Spectra Edition II Library were excited with an Nd:YVO4 laser (1064 nm) using laser powers between 400 - 600 mW, measured at the sample. A Thermo FT-Raman spectrometer (with a Ge detector) was used to collect the Raman spectra. The spectra were saved in Raman Shift format. Aldrich Raman Index Compound Name Index Compound Name 4803 ((1R)-(ENDO,ANTI))-(+)-3- 4246 (+)-3-ISOPROPYL-7A- BROMOCAMPHOR-8- SULFONIC METHYLTETRAHYDRO- ACID, AMMONIUM SALT PYRROLO(2,1-B)OXAZOL-5(6H)- 2207 ((1R)-ENDO)-(+)-3- ONE, BROMOCAMPHOR, 98% 12568 (+)-4-CHOLESTEN-3-ONE, 98% 4804 ((1S)-(ENDO,ANTI))-(-)-3- 3774 (+)-5,6-O-CYCLOHEXYLIDENE-L- BROMOCAMPHOR-8- SULFONIC ASCORBIC ACID, 98% ACID, AMMONIUM SALT 11632 (+)-5-BROMO-2'-DEOXYURIDINE, 2208 ((1S)-ENDO)-(-)-3- 97% BROMOCAMPHOR, 98% 11634 (+)-5-FLUORODEOXYURIDINE, 769 ((1S)-ENDO)-(-)-BORNEOL, 99% 98+% 13454 ((2S,3S)-(+)- 11633 (+)-5-IODO-2'-DEOXYURIDINE, 98% BIS(DIPHENYLPHOSPHINO)- 4228 (+)-6-AMINOPENICILLANIC ACID, BUTANE)(N3-ALLYL)PD(II) CL04, 96% 97 8167 (+)-6-METHOXY-ALPHA-METHYL- 10297 ((3- 2- NAPHTHALENEACETIC ACID, DIMETHYLAMINO)PROPYL)TRIPH 98% ENYL- PHOSPHONIUM BROMIDE, 12586 (+)-ANDROSTA-1,4-DIENE-3,17- 99% DIONE, 98% 13458 ((R)-(+)-2,2'- 963 (+)-ARABINOGALACTAN BIS(DIPHENYLPHOSPHINO)-1,1'-
    [Show full text]
  • Colorimetric Approaches to Drug Analysis and Applications – a Review
    REVIEW ARTICLE Am. J. PharmTech Res. 2019; 9(01) ISSN: 2249-3387 Journal home page: http://www.ajptr.com/ Colorimetric Approaches To Drug Analysis And Applications – A Review Sowjanya Gummadi*, Mohana Kommoju Department of Pharmaceutical Analysis, Institute of Pharmacy, GITAM (Deemed to be University), Visakhapatnam-530045, Andhra Pradesh, India ABSTRACT The main purpose of this review is to highlight the importance of colorimetric approaches to drug analysis both in dosage forms as well as biological samples. Colorimetric methods using colorimetric reagents are highly sensitive, specific and an easy way of determining various analytes in a variety of matrices within a short time. The colorimetric procedures discussed are statistically validated and reported in various quality control laboratories. Hence in the present review significance of colorimetric procedures, various reagents used along with principles and applications are mentioned. Key words: Colorimetric approaches, sensitive, matrices, quality control, applications. *Corresponding Author Email: [email protected] Received 01 November 2018, Accepted 23 December 2018 Please cite this article as: Gummadi S et al., Colorimetric Approaches To Drug Analysis And Applications – A Review. American Journal of PharmTech Research 2019. Gummadi et. al., Am. J. PharmTech Res. 2019; 9(01) ISSN: 2249-3387 INTRODUCTION Colorimetry is a technique which involves the quantitative estimation of colors frequently used in biochemical investigation. Color can be produced by any substance when it binds with color forming chromogens. The difference in color intensity results in difference in the absorption of light. The intensity of color is directly proportional to the concentration of the compound being measured.1 Wavelength between 380 nm to 780 nm forms the visible band of light in electromagnetic spectrum.
    [Show full text]
  • Moves to Amend HF No. 2711 As Follows
    05/05/20 ​ REVISOR KLL/JK A20-0767​ 1.1 .................... moves to amend H.F. No. 2711 as follows:​ 1.2 Delete everything after the enacting clause and insert:​ 1.3 "ARTICLE 1​ 1.4 APPROPRIATIONS​ 1.5 Section 1. APPROPRIATIONS.​ 1.6 The sums shown in the column under "APPROPRIATIONS" are added to or reduce the​ 1.7 appropriations in Laws 2019, First Special Session chapter 5, to the agencies and for the​ 1.8 purposes specified in this article. The appropriations are from the general fund, or another​ 1.9 named fund, and are available for the fiscal year indicated for each purpose.​ 1.10 APPROPRIATIONS​ 1.11 Available for the Year​ 1.12 Ending June 30​ 1.13 2020​ 2021​ 1.14 Sec. 2. CORRECTIONS​ 1.15 Subdivision 1. Total Appropriation​ $​ 205,000​ $​ 5,545,000​ 1.16 The amounts that may be spent for each​ 1.17 purpose are specified in the following​ 1.18 subdivisions.​ 1.19 Subd. 2. Correctional Institutions​ -0-​ (2,545,000)​ 1.20 To account for overall bed impact savings of​ 1.21 reductions in the penalties for controlled​ 1.22 substances offenses involving the possession​ 1.23 of marijuana, investments in community​ 1.24 supervision, and increased penalties for sex​ 1.25 trafficking offenses, the fiscal year 2021​ Article 1 Sec. 2.​ 1​ 05/05/20 ​ REVISOR KLL/JK A20-0767​ 2.1 appropriation from Laws 2019, First Special​ 2.2 Session chapter 5, article 1, section 15,​ 2.3 subdivision 2, is reduced by $2,545,000.​ 2.4 Subd.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • Monoamine Oxidase Inhibitory Properties of Some Methoxylated and Alkylthio Amphetamine Derivatives Strucrure-Acfivity RELA TIONSHIPS Ma
    Biochemieal PhannaeoloR)'. Vol. 54. pp. 1361-1369, 1997. ISSN 0006-2952/97/$17.00 + 0.00 © 1997 Elsevier Scienee Ine. Al! rights reserved. PIl SOOO6-2952(97)00405·X ELSEVIER Monoamine Oxidase Inhibitory Properties of Some Methoxylated and Alkylthio Amphetamine Derivatives STRUcruRE-ACfIVITY RELA TIONSHIPS Ma. Cecilia Scorza,* Cecilia Carrau,* Rodolfo Silveira,* GemId Zapata,Torres,t Bruce K. Casselst and Miguel Reyes,Parada*t *DIVISIÓNBIOLOGíACELULAR,INSTITUTODEINVESTIGACIONESBIOLÓGICASCLEMENTeEsTABlE, CP 11600, MONTEVIOEO,URUGUAY;ANDtDEPARTAMENTODEQUíMICA, FACULTADDECIENCIAS,UNIVERSIDADDECHILE, SANTIAGO,CHILE ABSTRACT. The monoamine oxidase (MAO) inhibitory propenies of a series of amphetamine derivatives with difTerent substituents at or around rhe para position of the aromaric ring were evaluateJ. i¡, in viero stuJies in which a crude rar brain mirochllndrial suspension was used as rhe source of MAO, several compounds showed a srrong (ICS0 in rhe submicromolar range), selecrive, reversible, time-independenr, and concenrrarion-related inhibition of MAO-A. After i.p. injection, the compounds induced an inerease of serotonin and a decrease of j-hydroxyindoleacetic acid in the raphe nuclei and hippocampus, confinning rhe in virro results. The analysis of structure-activity relationships indicates rhat: molecules with amphetamine-Iike structure and different substitutions nn the aromaric ring are potentially MAO-A inhibitors; substituents at different positions of the aromatic ring moditY the porency but have litde inf1uence "n the selectiviry; substituents at rhe para position sllch as ,lmino, alkoxyl. halogens. or alkylthio produce a significant increase in rhe acrivity; the para-substituent musr be an e1ectron Jonor; hulky ~roups next to rhe para subsriruent Icad ro a Jecrease in the actÍ\'ityi ,ubstiruents loearcd ar posirions more Jistant ,m rhe aromaric ring havc less intluence anJ, even when the subsriruent is '1 halogen (CI, Br), an increase in rhe acrivity "f rhe cllmpound is llbtained.
    [Show full text]
  • Virginia Acts of Assembly -- 2021 Special Session I
    VIRGINIA ACTS OF ASSEMBLY -- 2021 SPECIAL SESSION I CHAPTER 110 An Act to amend and reenact §§ 3.2-4112, 3.2-4113, 3.2-4114.2, 3.2-4115, 3.2-4116, 3.2-4118, 3.2-4119, 18.2-247, 18.2-251.1:3, 54.1-3401, and 54.1-3446 of the Code of Virginia, relating to industrial hemp; emergency. [H 2078] Approved March 12, 2021 Be it enacted by the General Assembly of Virginia: 1. That §§ 3.2-4112, 3.2-4113, 3.2-4114.2, 3.2-4115, 3.2-4116, 3.2-4118, 3.2-4119, 18.2-247, 18.2-251.1:3, 54.1-3401, and 54.1-3446 of the Code of Virginia are amended and reenacted as follows: § 3.2-4112. Definitions. As used in this chapter, unless the context requires a different meaning: "Cannabis sativa product" means a product made from any part of the plant Cannabis sativa, including seeds thereof and any derivative, extract, cannabinoid, isomer, acid, salt, or salt of an isomer, whether growing or not, with a concentration of tetrahydrocannabinol that is greater than that allowed by federal law. "Deal" means to buy temporarily possess industrial hemp grown in compliance with state or federal law and to sell such industrial hemp to a person who that (i) processes industrial hemp in compliance with state or federal law or has not been processed and (ii) sells industrial hemp to a person who processes industrial hemp in compliance with state or federal law was not grown and will not be processed by the person temporarily possessing it.
    [Show full text]
  • Synthetic Cannabinoids (60 Substances) A) Classical Cannabinoid
    Synthetic cannabinoids (60 substances) a) Classical cannabinoid OH H OH H O Common name Chemical name CAS number Molecular Formula HU-210 3-(1,1’-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1- Synonym: 112830-95-2 C H O hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol 25 38 3 11-Hydroxy-Δ-8-THC-DMH b) Nonclassical cannabinoids OH OH R2 R3 R4 R1 CAS Molecular Common name Chemical name R1 R2 R3 R4 number Formula rel-2[(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methyloctan- 2- yl) CP-47,497 70434-82-1 C H O CH H H H phenol 21 34 2 3 rel-2[(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methylheptan- 2- yl) CP-47,497-C6 - C H O H H H H phenol 20 32 2 CP-47,497-C8 rel-2- [(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methylnonan- 2- yl) 70434-92-3 C H O C H H H H Synonym: Cannabicyclohexanol phenol 22 36 2 2 5 CAS Molecular Common name Chemical name R1 R2 R3 R4 number Formula rel-2[(1 S,3 R)-3- hydroxycyclohexyl]- 5- (2- methyldecan- 2- yl) CP-47,497-C9 - C H O C H H H H phenol 23 38 2 3 7 rel-2- ((1 R,2 R,5 R)-5- hydroxy- 2- (3- hydroxypropyl)cyclohexyl)- 3-hydroxy CP-55,940 83003-12-7 C H O CH H H 5-(2- methyloctan- 2- yl)phenol 24 40 3 3 propyl rel-2- [(1 S,3 R)-3- hydroxy-5,5-dimethylcyclohexyl]- 5- (2- Dimethyl CP-47,497-C8 - C H O C H CH CH H methylnonan-2- yl)phenol 24 40 2 2 5 3 3 c) Aminoalkylindoles i) Naphthoylindoles 1' R R3' R2' O N CAS Molecular Common name Chemical name R1’ R2’ R3’ number Formula [1-[(1- methyl- 2- piperidinyl)methyl]- 1 H-indol- 3- yl]- 1- 1-methyl-2- AM-1220 137642-54-7 C H N O H H naphthalenyl-methanone 26 26 2 piperidinyl
    [Show full text]
  • Article 22 Regulation for Restriction of Synthetic Drugs
    ARTICLE 22 REGULATION FOR RESTRICTION OF SYNTHETIC DRUGS SECTION 22.1 AUTHORITY This regulation is promulgated under the authority granted to the Needham Board of Health under Massachusetts General Laws Chapter 111, Section 31 which states that “boards of health may make reasonable health regulations”. SECTION 22.2 PURPOSE The Needham Board of Health has found that synthetic marijuana, consisting of plant or other material treated with various chemicals or other synthetic substances not approved for human consumption, may be marketed and sold as herbal incense in the greater Boston area, although they are being used in the same manner and for the same purposes as scheduled drugs. In addition, the use of these products has become particularly popular among teens and young adults. Based on information and reports from hospitals, emergency room doctors, and police agencies, individuals who use these products experience dangerous side effects including convulsions, hallucinations, and dangerously elevated heart rates. This is evidence that synthetic marijuana products are harmful if inhaled or consumed, and present a significant public health danger. These synthetic compounds and others have a high potential for abuse and lack of any accepted medical use, these dangerous products, while not approved for human consumption, are marketed and sold in a form that allows for such consumption, putting at risk the individuals who come into contact with them. Therefore, the Needham Board of Health adopts this regulation for the purpose and with the intent to protect the public health and safety of the Town of Needham and its residents from the threat posed by the availability and use of synthetic marijuana, synthetic stimulants, synthetic hallucinogens, and other dangerous products by prohibiting persons from trafficking in, possessing, and using them within the town.
    [Show full text]